Pharmacological Inhibition of Lipid Import and Transport Proteins in Ovarian Cancer

被引:8
|
作者
Lemberger, Lisa [1 ]
Wagner, Renate [1 ,2 ]
Heller, Gerwin [2 ,3 ]
Pils, Dietmar [2 ,4 ]
Grunt, Thomas W. [1 ,2 ,5 ]
机构
[1] Med Univ Vienna, Dept Med 1, Div Oncol, Cell Signaling & Metab Networks Program, A-1090 Vienna, Austria
[2] Med Univ Vienna, Comprehens Canc Ctr, A-1090 Vienna, Austria
[3] Med Univ Vienna, Dept Med 1, Div Oncol, A-1090 Vienna, Austria
[4] Med Univ Vienna, Dept Gen Surg, Div Visceral Surg, A-1090 Vienna, Austria
[5] Ludwig Boltzmann Inst Hematol & Oncol, A-1090 Vienna, Austria
关键词
fatty acid; import; inhibitor; lipid; lipid handling protein; molecular targeting; ovarian cancer; transport; uptake; FATTY-ACID SYNTHASE; BINDING-PROTEINS; ADIPOSE-TISSUE; RETINOIC ACID; C-ERBB; CELLS; EXPRESSION; METABOLISM; PROGRESSION; METASTASIS;
D O I
10.3390/cancers14236004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Ovarian cancer (OC) is still the most lethal gynecological cancer due to late diagnosis when peritoneal metastasis has already occurred. OC progression requires lipid nutrients that are either synthesized endogenously in the cancer cells or imported from the surrounding host tissue. Accordingly, blockade of lipid synthesis has been shown to be a powerful strategy against OC. However, direct evidence of the role of lipid import and transport for OC cell growth is still largely missing. Therefore, we exposed OC cells to inhibitors of lipid uptake and transport proteins, which are typically overexpressed in OC. Our data reveal that pharmacological inhibition of these lipid handling proteins caused a drug-specific, dose-/time-dependent decline of lipid uptake, which was associated with cell growth reduction, cell cycle arrest, and apoptosis, indicating that OC cells are exquisitely sensitive to lipid deficiency. This dependency provides the rationale for the development of novel lipid-antimetabolic strategies against OC. Ovarian cancer (OC) is the most lethal gynecological malignancy with a 5-year survival rate of 49%. This is caused by late diagnosis when cells have already metastasized into the peritoneal cavity and to the omentum. OC progression is dependent on the availability of high-energy lipids/fatty acids (FA) provided by endogenous de novo biosynthesis and/or through import from the microenvironment. The blockade of these processes may thus represent powerful strategies against OC. While this has already been shown for inhibition of FA/lipid biosynthesis, evidence of the role of FA/lipid import/transport is still sparse. Therefore, we treated A2780 and SKOV3 OC cells with inhibitors of the lipid uptake proteins fatty acid translocase/cluster of differentiation 36 (FAT/CD36) and low-density lipoprotein (LDL) receptor (LDLR), as well as intracellular lipid transporters of the fatty acid-binding protein (FABP) family, fatty acid transport protein-2 (FATP2/SLC27A2), and ADP-ribosylation factor 6 (ARF6), which are overexpressed in OC. Proliferation was determined by formazan dye labeling/photometry and cell counting. Cell cycle analysis was performed by propidium iodide (PI) staining, and apoptosis was examined by annexin V/PI and active caspase 3 labeling and flow cytometry. RNA-seq data revealed altered stress and metabolism pathways. Overall, the small molecule inhibitors of lipid handling proteins BMS309403, HTS01037, NAV2729, SB-FI-26, and sulfosuccinimidyl oleate (SSO) caused a drug-specific, dose-/time-dependent inhibition of FA/LDL uptake, associated with reduced proliferation, cell cycle arrest, and apoptosis. Our findings indicate that OC cells are very sensitive to lipid deficiency. This dependency should be exploited for development of novel strategies against OC.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] FUNCTIONAL ASPECTS OF PROTEINS INVOLVED IN LIPID TRANSPORT
    ERKELENS, DW
    NETHERLANDS JOURNAL OF MEDICINE, 1978, 21 (03): : 129 - 137
  • [22] LIPID MODIFICATION OF PROTEINS AND THEIR MEMBRANE-TRANSPORT
    KABANOV, AV
    LEVASHOV, AV
    ALAKHOV, VY
    PROTEIN ENGINEERING, 1989, 3 (01): : 39 - 42
  • [23] SERUM LIPID PROFILES IN OVARIAN CANCER
    Lv, Q.
    Xiaojun, C.
    Congjian, X.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 759 - 759
  • [24] Association of lipid metabolism with ovarian cancer
    Tania, M.
    Khan, M. A.
    Song, Y.
    CURRENT ONCOLOGY, 2010, 17 (05) : 6 - 11
  • [25] INHIBITION OF LIPID TRANSPORT IN INSECTS BY A PARASITIC FACTOR
    HAYAKAWA, Y
    COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 1987, 87 (02): : 279 - 283
  • [26] Mitochondrial phospholipid transport: Role of contact sites and lipid transport proteins
    Mavuduru, Vijay Aditya
    Vadupu, Lavanya
    Ghosh, Krishna Kanta
    Chakrabortty, Sabyasachi
    Gulyas, Balazs
    Padmanabhan, Parasuraman
    Ball, Writoban Basu
    PROGRESS IN LIPID RESEARCH, 2024, 94
  • [27] ENDOGENOUS PROTEINS OF OLFACTORY NEURONS USE THE RETROGRADE TRANSPORT NUCLEAR IMPORT PATHWAY
    HUANG, CC
    HUANG, TY
    AMBRON, RT
    JOURNAL OF NEUROCHEMISTRY, 1995, 65 : S186 - S186
  • [28] PARP Inhibition in Recurrent Ovarian Cancer
    Moore, Kathleen N.
    Pothuri, Bhavana
    Monk, Bradley
    Coleman, Robert L.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (10) : 647 - 655
  • [29] Histone deacetylase inhibition in ovarian cancer
    Wine, I. S.
    Tan, L.
    Kwok, R.
    Opipari, A. W.
    Liu, J.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S35 - S36
  • [30] Immune checkpoint inhibition in ovarian cancer
    Hamanishi, Junzo
    Mandai, Masaki
    Konishi, Ikuo
    INTERNATIONAL IMMUNOLOGY, 2016, 28 (07) : 339 - 348